Functional Technologies Corp.
TSX VENTURE : FEB

Functional Technologies Corp.

September 01, 2010 07:00 ET

Functional Technologies Reports Positive Results of Novel Malaria Treatment Trials

Yeast neutralizes malarial parasites in mice without side effects

TORONTO, ONTARIO--(Marketwire - Sept. 1, 2010) - Functional Technologies Corp., (TSX VENTURE:FEB), in cooperation with University of Toronto scientists, today announced promising initial results of a revolutionary yeast-based approach for the treatment of malaria. In pre-clinical proof-of-concept tests involving four separate animal trials (mouse models), including one looking at uptake and three for potency, a positive effect against malaria was demonstrated using Functional Technologies' specifically enhanced yeast. Importantly, no toxicity was reported, even at 100 times the effective dosage.

In this novel approach to malaria treatment, the yeast is used both to produce and deliver a protein that neutralizes malarial parasites. After the protein-laden yeast is ingested, the active proteins bind to the parasites in the bloodstream, rendering them benign. In sharp contrast to conventional and widely used chemical treatments that often pose significant side effects for the patient, Functional Technologies' yeast application has not shown such side effects at the doses used in the preliminary mice studies. In the aforementioned mouse trials, the anti-malarial protein was detectable in the bloodstream after oral administration; the company believes this indicates the potential for an orally-applied product. Oral dosing is generally considered the most cost-effective, safe and convenient method available for treatment programs in impoverished countries.

Dr. Ian Crandall, a leading malaria researcher and professor of pharmaceutical sciences at the University of Toronto, working with Dr. Subrata Chowdhury, the company's primary scientist on the project, directed the testing of the malaria-infected mice. Dr. Crandall commented: "As far as I am aware, this is a totally fresh approach to malaria treatment that is showing early and promising efficacy and safety. It presents a completely new area of study alongside the traditional ways in which malaria has been addressed through synthetic drugs. We may be onto something very exciting, and I look forward to being involved in the next phases of research." 

Garth Greenham, president and chief operating officer of Functional Technologies Corp., commented on the study: "Our purpose in releasing these proof-of-concept results is to make potential partners and collaborators aware of our malaria program, and help accelerate testing and development of this potentially safe, natural and cost-effective treatment." Greenham added, "Our yeast-based solution needs to be investigated thoroughly to determine its potential for improving human health, and specifically in many of the world's most at-risk populations."

Pre-clinical Trials and Company Background 

The animal proof-of-concept studies for efficacy involved groups of 20 infected mice in four cohorts treated at different dosage levels. Positive results included a statistically significant reduction and delay in the onset of malarial symptoms, and an improvement in the health status in the test group versus the control group. In addition, the test group showed a slowing of the weight loss that accompanies malaria infection. Dr. Crandall commented on the results: "Although the number of animals used in the tests was limited, the results strongly suggest that the animals receiving the active protein were both healthier and had a reduced number of parasites. Given the difficulties in optimizing the most effective dosing, timing and delivery in preliminary mouse models, my opinion is that by improving these treatment details we could achieve a complete cure in mouse infections. Of course, there's a long way to go for human treatment, but these are very interesting results that merit further study."

Functional Technologies' research and development has focused on highly advanced proprietary technologies to enhance the natural properties of yeast and algae, two of nature's microscopic workhorses. Yeast is widely accepted as a safe food technology and is currently used in the production of numerous consumer foods and beverages. In addition to focusing on resolving food safety and quality issues, the company's scientists have long been researching the use of yeast biologics for drug delivery.

The company's malaria program was developed over the last two years by an in-house research team led by Subrata Chowdhury, PhD. Planning and implementation of these animal model studies took place over the last 12 months and the analysis was completed over the last two months.

Facts on Malaria

Malaria, a mosquito-borne parasitic disease, remains one the world's most significant health problems, annually infecting over 250 million people and claiming almost one million lives, the majority of them children in sub-Saharan Africa. Symptoms, which include fever, headache and vomiting, usually appear 10–15 days after a person is bitten by a mosquito. Left untreated, malaria can quickly become life-threatening by disrupting the blood supply to vital organs and causing an overwhelming inflammatory response. 

About half of the world's population is at risk for malaria, which is also a major threat in Asia and Latin America, and to a lesser extent in the Middle East and parts of Europe. According to the World Health Organization, in 2008 the disease was present in more than 100 countries and territories. While there are about a dozen different drugs used to treat malaria, in many parts of the world the parasites have developed resistance. As such, there is a desperate need for new classes of anti-malarial treatments, particularly ones that can be delivered in a manner that suits rural and impoverished populations. Governments, aid agencies and the private sector, notably the Bill and Melinda Gates Foundation, spend almost $2 billion annually fighting malaria by sending medicines and supplies to countries hard-hit by this deadly infection.

About Functional Technologies Corp.

Functional Technologies Corp. develops and commercializes proprietary technologies that enhance the natural properties of yeast and algae — nature's microscopic workhorses. Our scientists apply novel techniques to these micro-celled organisms to resolve significant health and quality problems, and generate new opportunities in the global food, beverage and healthcare industries. Our first commercial products are our Phyterra™ line of proprietary yeast strains, designed to reduce the formation of foul-smelling hydrogen sulfide and the carcinogen urethane in wines and other fermented products. With a head office in Vancouver, Functional Technologies Corp. has R&D facilities in Prince Edward Island and a U.S. sales office in Napa Valley, California. For more information go to www.functionaltechcorp.com.

FORWARD-LOOKING STATEMENTS: This news release contains forward-looking statements about Functional Technologies Corp. and its future plans. Forward-looking statements are statements that are not historical facts, and in this news release include the statements as to (1) the potential of Functional Technologies' malaria treatment to effectively treat malaria in mice or humans; and (2) that tests indicate that there is no toxicity or negative side effects in Functional Technologies' malaria treatment; and (3) that the treatment could be used to cost-effectively treat humans. The forward-looking statements in this news release are subject to various risks, uncertainties and other factors that could cause the company's actual results or achievements to differ materially from those expressed in, or implied by, the forward-looking statements. These risks, uncertainties and other factors include, without limitation, uncertainty as to the company's ability to achieve the goals and satisfy the assumptions of management; uncertainty as to the company's ability to obtain partners to carry out research, development, approval and distribution of this treatment products; and other factors that may be beyond the control of the company. Forward-looking statements are based on the beliefs, opinions and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions or expectations, or other circumstances, should change. Reference is made to the section entitled "Risks and Uncertainties" commencing on page 16 of the company's management's discussion and analysis relating to the fiscal quarter ended May 31, 2010, which is available on SEDAR at www.sedar.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact Information